What We're Reading: Page 146
Industry reads hand-picked by our editors
Sep 23, 2021
-
POLITICO
Pfizer CEO rallies staff to fight Democrats' drug price negotiation
-
Bloomberg
Vaccinated Pregnant Women Pass Protection to Babies in Study
-
Financial Times
Activist Bluebell takes stake in GlaxoSmithKline to push for change at top
-
Evaluate Vantage
The heat is on Gilead as Tropics readout nears
Sep 22, 2021
-
STAT
Biogen considers cost-cutting measures after slow Aduhelm sales
-
The New York Times
Pressure Grows on U.S. Companies to Share Covid Vaccine Technology
-
Fierce Pharma
Amgen scores Otezla patent win, nabbing protection until 2028
-
NPR
The FDA Has Been Without A Permanent Leader For 8 Months, As COVID Cases Climb
Sep 21, 2021
Sep 20, 2021
Sep 17, 2021
-
Endpoints News
The biggest questions facing gene therapy, the XLMTM community, and Astellas after fourth patient death
-
Evaluate Vantage
Biogen leads the amyotrophic lateral sclerosis hopefuls
-
STAT
New study revives a Mozart sonata as a potential epilepsy therapy
-
Reuters
China's biotech sector comes of age with big licensing deals, global ambitions
Sep 16, 2021
-
The Washington Post
At the besieged FDA, ‘it never stops!’ as decisions loom on boosters, pediatric shots and more
-
Business Insider
How China quietly grew into a biotech powerhouse that will shape the future of the drug industry
-
The New York Times
Democrats’ Stumble on Drug Prices Shows Power of Industry
-
Kaiser Health News
How Fauci and the NIH Got Ahead of the FDA and CDC in Backing Boosters
Sep 15, 2021
-
Bloomberg Government
Drug Pricing Opponents Complicate Democrats' Health Ambitions
-
Nature
The tangled history of mRNA vaccines
-
FierceBiotech
Sanofi dumps Principia Biopharma's San Francisco labs with plans to immediately cut 38 jobs
-
Evaluate Vantage
Front-line competition lines up behind Keytruda
Previous
